, Volume 25, Issue 1, pp 91–97 | Cite as

Antinociceptive interaction of gabapentin with minocycline in murine diabetic neuropathy

  • H. F. MirandaEmail author
  • F. Sierralta
  • V. Jorquera
  • P. Poblete
  • J. C. Prieto
  • V. Noriega
Original Article



Diabetic neuropathy (DN) is the most common complication of diabetes and pain is one of the main symptoms of diabetic neuropathy, however, currently available drugs are often ineffective and complicated by adverse events. The purpose of this research was to evaluate the antinociceptive interaction between gabapentin and minocycline in a mice experimental model of DN by streptozocin (STZ).


The interaction of gabapentin with minocycline was evaluated by the writhing and hot plate tests at 3 and 7 days after STZ injection or vehicle in male CF1 mice.


STZ (150 mg/kg, i.p.) produced a marked increase in plasma glucose levels on day 7 (397.46 ± 29.65 mg/dL) than on day 3 (341.12 ± 35.50 mg/dL) and also developed neuropathic pain measured by algesiometric assays. Gabapentin produced similar antinociceptive activity in both writhing and hot plate tests in mice pretreated with STZ. However, minocycline was more potent in the writhing than in the hot plate test in the same type of mice. The combination of gabapentin with minocycline produced synergistic interaction in both test.


The combination of gabapentin with minocycline in a 1:1 proportion fulfills all the criteria of multimodal analgesia and this finding suggests that the combination provide a therapeutic alternative that could be used for human neuropathic pain management.


Neuropathy Diabetes Streptozocin Minocycline Gabapentin Synergism 



This work was partially supported by project from Andres Bello University.

Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interest in this manuscript.


  1. Bijnsdorp IV, Giovannetti E, Peters G (2011) Analysis of drug interactions. Methods Mol Biol 731:421–434CrossRefPubMedGoogle Scholar
  2. Chaudhry ZZ, Morris DL, Moss DR, Sims EK, Chiong Y, Kono T, Evans-Molina C (2013) Streptozocin is equally diabetogenic whether administered to fed or fasted mice. Lab Anim 47:257–265CrossRefPubMedPubMedCentralGoogle Scholar
  3. Cheng JK, Chiou LC (2006) Mechanisms of the antinoceptive action of gabapentin. J Pharmacol Sci 100:471–486CrossRefPubMedGoogle Scholar
  4. Cho IH, Lee MJ, Jang M, Gwak NG, Lee KY, Jung HS (2012) Minocycline markedly reduces acute visceral nociception via inhibiting neuronal ERK phosphorylation. Mol Pain 24:8–13Google Scholar
  5. Colleoni M, Sacerdote P (2010) Murine models of human neuropathic pain. Biochim Biophys Acta 1802:924–933CrossRefPubMedGoogle Scholar
  6. Feng Y, Cui M, Willis WD (2003) Gabapentin markedly reduces acetic acid-induced visceral nociception. Anesthesiology 98:729–733CrossRefPubMedGoogle Scholar
  7. Gao F, Zheng ZM (2014) Animal models of diabetic. Exp Clin Endocrinol Diabetes 122:100–106CrossRefPubMedGoogle Scholar
  8. Goldstein A, Aronov L, Kalman SM (1974) Principles of drug action, 2nd edn. Wiley, New York, pp 89–96Google Scholar
  9. IASP (2015) Pain clinical update. Halting the march of painful diabetic neuropathy. Pain 4:1–8Google Scholar
  10. Ik-Hyun C, Lee CNM, Gwak G, Lee Y (2012) Minocycline markedly reduces acute visceral nociception via inhibiting neuronal ERK phosphorylation. Mol Pain 8:13–26Google Scholar
  11. Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD, Rice ASC, Treede RD (2011) A new definition of neuropathic pain. Pain 152:2204–2205CrossRefPubMedGoogle Scholar
  12. Kilic FS, Sirmagul B, Yildirim E, Oner S, Erol K (2012) Antinociceptive effects of gabapentin & its mechanism of action in experimental animal studies. Indian J Med Res 135:630–635PubMedPubMedCentralGoogle Scholar
  13. Kim TH, Kim HI, Kim J, Park M, Song JH (2011) Effects of minocycline on Na+ currents in rat dorsal root ganglion neurons. Brain Res 1370:34–42CrossRefPubMedGoogle Scholar
  14. King J (2012) The use of animal models in diabetes research. J Pharmacol 166:877–894Google Scholar
  15. Li D, Liang X, Sun B, Ding X, Han H, Rong W, Zhang G (2015) Impairments of the primary afferent nerves in a rat model of diabetic visceral hyposensitivity. Mol Pain 11:74–81Google Scholar
  16. Miranda HF, Noriega V, Olavarría L, Zepeda RJ, Sierralta F, Prieto JC (2001) Antinocicepcion and anti-inflammation induced by simvastatin in algesiometric assay in mice. Basic Clin Pharmacol Toxicol 109:438–442CrossRefGoogle Scholar
  17. Miranda HF, Sierralta F, Pinardi G (2002) Neostigmine interactions with non steroidal anti-inflammatory drugs. Br J Pharmacol 135:1591–1597CrossRefPubMedPubMedCentralGoogle Scholar
  18. Miranda HF, Puig MM, Prieto JC, Pinardi G (2006) Synergism between paracetamol and nonsteroidal anti-inflammatory drugs in experimental acute pain. Pain 121:22–28CrossRefPubMedGoogle Scholar
  19. Obrosova IG (2009) Diabetic painful and insensate neuropathy: pathogenesis and potential treatments. Neurotherapeutics 6:638–647CrossRefPubMedPubMedCentralGoogle Scholar
  20. Pabreja K, Dua K, Sharma S, Padi SS, Kulkarni SK (2011) Minocycline attenuates the development of diabetic neuropathic pain: possible anti-inflammatory and anti-oxidant mechanisms. Eur J Pharmacol 661:15–21CrossRefPubMedGoogle Scholar
  21. Padi SS, Kulkarni SK (2008) Minocycline prevents the development of neuropathic pain, but not acute pain: possible anti-inflammatory and antioxidant mechanisms. Eur J Pharmacol 601:79–87CrossRefPubMedGoogle Scholar
  22. Schreiber AK, Nones CFM, Reis RC, Chichorro JG, Cunha JM (2015) Diabetic neuropathic pain: physiopathology and treatment. World J Diabetes 6:432–444CrossRefPubMedPubMedCentralGoogle Scholar
  23. Stepanovic-Petrovic RM, Tomic MA, Vuckovic SM, Paranos S, Ugresic ND, Prostran MS, Milovanovic S, Boskovic B (2008) The antinociceptive effects of anticonvulsants in a mouse visceral pain model. Anesth Analg 106:1897–1903CrossRefPubMedGoogle Scholar
  24. Syngle A, Verma I, Krishan P, Garg N, Syngle V (2014) Minocycline improves peripheral and autonomic neuropathy in type 2 diabetes: MIND study. Neurol Sci 35:1067–1073CrossRefPubMedGoogle Scholar
  25. Tallarida RJ (2000) Drug synergism and dose-effect data analysis. Chapman and Hall/CRC, Boca Raton, pp 26–131CrossRefGoogle Scholar
  26. Tallarida RJ (2001) Drug synergism: its detection and applications. Pharmacol Exp Ther 298:865–872Google Scholar
  27. Vanelderen P, Rouwette T, Kozicz T, Heylen R, Van Zundert J, Roubos EW, Vissers K (2013) Effects of chronic administration of amitriptyline, gabapentin and minocycline on spinal brain-derived neurotrophic factor expression and neuropathic pain behavior in a rat chronic constriction injury model. Reg Anesth Pain Med 38:124–130CrossRefPubMedGoogle Scholar
  28. Veves A, Backonja M, Malik RA (2008) Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options. Pain Med 9:660–674CrossRefPubMedGoogle Scholar
  29. Wodarski R, Clark AK, Grist J, Marchand F, Malcangio M (2009) Gabapentin reverses microglial activation in the spinal cord of streptozotocin-induced diabetic rats. Eur J Pain 13:807–811CrossRefPubMedGoogle Scholar
  30. Wu J, Yang LJ (2015) Streptozocin-induced type 1 diabetes in rodents as a model for studying mitochondrial mechanisms of diabetic β cell glucotoxicity. Diabetes Metab Syndr Obes Targets Ther 8:181–188Google Scholar

Copyright information

© Springer International Publishing 2017

Authors and Affiliations

  • H. F. Miranda
    • 1
    • 2
    Email author
  • F. Sierralta
    • 2
    • 3
  • V. Jorquera
    • 1
  • P. Poblete
    • 1
  • J. C. Prieto
    • 1
    • 4
  • V. Noriega
    • 1
    • 4
  1. 1.Faculty of Medicine, School of PharmacyAndres Bello UniversitySantiagoChile
  2. 2.Pharmacology Program, ICBM, Faculty of MedicineUniversity of ChileSantiagoChile
  3. 3.Faculty of OdontologyFinis Terrae UniversityProvidenciaChile
  4. 4.Cardiovascular Department, Clinic HospitalUniversity of ChileSantiagoChile

Personalised recommendations